NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Analysis By Type, By End-Use (Pharma & CRO Industry, Hospitals, Diagnostic Labs, Academic Research Institutes), And Segment Forecasts, 2014 – 2025

Categories: Drugs by Therapeutic Area, Liver and Kidney Disorders Drugs, Pharmaceuticals

Price: $4,950

Description

The global non-alcoholic steatohepatitis (NASH) biomarkers market is expected to reach USD 2.09 billion by 2025, according to this new report. Increasing incidence of chronic liver diseases is expected to propel the demand for NASH biomarkers over the forecast period. The National Health and Nutrition Examination Survey recently found that approximately 30% of Nonalcoholic Fatty Liver Diseases (NAFLD) occurred in the U.S. alone. This disease remains undiagnosed, as a liver can remain fatty without any change in its function. However, it can progress into a serious condition, known as nonalcoholic steatosis that may result in liver failure. NASH is characterized by inflammation and irreversible cell death.

Rising demand for non-invasive diagnostic tools for detection of NASH is another driver of market. Traditionally, liver biopsy is performed to diagnose NAFLD and its degenerative condition, that is, NASH. This technique is expensive and invasive in nature. This disadvantage has led to the development of noninvasive and cost-efficient diagnostic techniques such as biomarker tests. It is observed that many key companies spent significantly on research and development activities to introduce novel biomarker tests. These factors are expected to propel NASH biomarkers market in the coming years.

The drug manufacturers are focusing on tapping unmet medical needs for treatment of NASH to capture additional market share. Strategic collaborations, expansion in developing geographies, and technological advancements are some of the key strategies adopted by existing market players.

Further key findings from the report suggest:
- Serum biomarkers held majority of the revenue share as of 2016 owing to its high efficacy in NASH diagnosis
- Gamma-glutamyl transferase is the serum biomarker that is usually higher in patients with fatty liver diseases, resulting in liver failure
- Increasing list of patients awaiting liver transplantation is a major contributing factor for the growing demand of noninvasive biomarker tests over the forecast period
- Pharmaceutical and contract research industry dominate the end-use segment owing to ample availability of R&D funding and ongoing research projects for the development NASH drugs
- Industry participants are focusing on development of cost-effective solutions, thereby increasing R&D activities for development of novel technologies

* PLEASE NOTE: This report will be completed after order and will take approximately 1-2 business days after the confirmation of payment.

Table of Contents

1 Research Methodology
1.1 Country wise market: Base estimates
1.2 Global market: CAGR calculation
1.3 Region based segment share calculation
1.4 Research Scope & Assumptions
1.5 List of Data Sources

2. Executive Summary
2.1 Market Snapshot

3. NASH Biomarkers Market Variables, Trends & Scope
3.1 Market Segmentation & Scope
3.2 Market Driver Analysis
3.2.1 Increasing prevalence of chronic diseases
3.2.2 Increasing demand for non invasive diagnostics for NASH biomarkers
3.2.3 Rising investment by government and private organizations in R&D for NASH biomarkers therapeutics
3.3 Market Restraint Analysis
3.3.1 Side-effects and risks associated with NASH therapeutics
3.4 Penetration & Growth Prospect Mapping
3.5 NASH biomarkers- SWOT Analysis, By Factor (political & legal, economic and technological)
3.6 Industry Analysis - Porter’s

4. NASH Biomarkers Market: Type Estimates & Trend Analysis
4.1 NASH Biomarkers Market: Type Movement Analysis
4.2 Serum Biomarkers
4.2.1 Serum biomarkersmarket, 2014 - 2025 (USD Million)
4.3 Hepatic Fibrosis Biomarkers
4.3.1 Hepatic fibrosis biomarkers market, 2014 - 2025 (USD Million)
4.4 Apoptosis Biomarkers
4.4.1 Apoptosis biomarkers market, 2014 - 2025 (USD Million)
4.5 Oxidative Stress Biomarkers
4.5.1 Oxidative stress biomarkers market, 2014 - 2025 (USD Million)
4.6 Others
4.6.1 Others market, 2014 - 2025 (USD Million)

5. NASH Biomarkers Market: End-use Estimates & Trend Analysis
5.1 NASH biomarkersMarket: End-use Movement Analysis
5.2 Pharma & CRO Industry
5.2.1 Pharma & CRO industry market, 2014 - 2025 (USD Million)
5.3 Hospitals
5.3.1 Hospitalsmarket, 2014 - 2025 (USD Million)
5.4 Diagnostic Labs
5.4.1 Diagnostic Labs market, 2014 - 2025 (USD Million)
5.5 Academic Research Institutes
5.5.1 Academic research institutes Market, 2014 - 2025 (USD Million)

6. NASH biomarkers Market: Regional Estimates & Trend Analysis, by Type, and End-use
6.1 NASH biomarkersMarket Share by Region, 2016 & 2025
6.2 North America
6.2.1 North America NASH biomarkers market, by country, 2014 - 2025 (USD Million)
6.2.2 North America NASH biomarkers market, by type, 2014 - 2025 (USD Million)
6.2.3 North America NASH biomarkersmarket, by end-use, 2014 - 2025 (USD Million)
6.2.4 U.S.
6.2.4.1 U.S. NASH biomarkers market, by type, 2014 - 2025 (USD Million)
6.2.4.2 U.S. NASH biomarkers market, by end-use, 2014 - 2025 (USD Million)
6.2.5 Canada
6.2.5.1 Canada NASH biomarkers market, by type, 2014 - 2025 (USD Million)
6.2.5.2 Canada NASH biomarkers market, by end-use, 2014 - 2025 (USD Million)
6.3 Europe
6.3.1 Europe NASH biomarkers market, by country, 2014 - 2025 (USD Million)
6.3.2 Europe NASH biomarkers market, by type, 2014 - 2025 (USD Million)
6.3.3 Europe NASH biomarkers market, by end-use, 2014 - 2025 (USD Million)
6.3.4 Germany
6.3.4.1 Germany NASH biomarkers market, by type, 2014 - 2025 (USD Million)
6.3.4.2 Germany NASH biomarkers market, by end-use, 2014 - 2025 (USD Million)
6.3.5 UK
6.3.5.1 UK NASH biomarkers market, by type, 2014 - 2025 (USD Million)
6.3.5.2 UK NASH biomarkers market, by end-use, 2014 - 2025 (USD Million)
6.4 Asia Pacific
6.4.1 Asia PacificNASH biomarkers market, by country, 2014 - 2025 (USD Million)
6.4.2 Asia Pacific NASH biomarkers market, by type, 2014 - 2025 (USD Million)
6.4.3 Asia Pacific NASH biomarkers market, by end-use, 2014 - 2025 (USD Million)
6.4.4 Japan
6.4.4.1 Japan NASH biomarkers market, by type, 2014 - 2025 (USD Million)
6.4.4.2 Japan NASH biomarkers market, by end-use, 2014 - 2025 (USD Million)
6.4.5 China
6.4.5.1 China NASH biomarkers market, by type, 2014 - 2025 (USD Million)
6.4.5.2 China NASH biomarkers market, by end-use, 2014 - 2025 (USD Million)
6.4.6 India
6.4.6.1 India NASH biomarkers market, by type, 2014 - 2025 (USD Million)
6.4.6.2 India NASH biomarkers market, by end-use, 2014 - 2025 (USD Million)
6.5 Latin America
6.5.1 Latin America NASH biomarkers market, by country, 2014 - 2025 (USD Million)
6.5.2 Latin America NASH biomarkers market, by type, 2014 - 2025 (USD Million)
6.5.3 Latin America NASH biomarkers market, by end-use, 2014 - 2025 (USD Million)
6.5.4 Brazil
6.5.4.1 Brazil NASH biomarkers market, by type, 2014 - 2025 (USD Million)
6.5.4.2 Brazil NASH biomarkers market, by end-use, 2014 - 2025 (USD Million)
6.5.5 Mexico
6.5.5.1 Mexico NASH biomarkers market, by type, 2014 - 2025 (USD Million)
6.5.5.2 Mexico NASH biomarkers market, by end-use, 2014 - 2025 (USD Million)
6.6 MEA
6.6.1 MEA NASH biomarkersmarket, by country, 2014 - 2025 (USD Million)
6.6.2 MEA NASH biomarkersmarket, by type, 2014 - 2025 (USD Million)
6.6.3 MEA NASH biomarkersmarket, by end-use, 2014 - 2025 (USD Million)
6.6.4 South Africa
6.6.4.1 South Africa NASH biomarkers market, by type, 2014 - 2025 (USD Million)
6.6.4.2 South Africa NASH biomarkers market, by end-use, 2014 - 2025 (USD Million)

7. Competitive Landscape
7.1 Strategy Framework
7.2 Market Participation
7.3 Company Profiles
7.3.1 GENFIT SA
7.3.1.1 Company overview
7.3.1.2 Financial performance
7.3.1.3 Products benchmarking
7.3.1.4 Geographic footprint
7.3.1.5 Strategic initiatives
7.3.2 Gilead Sciences, Inc. (GILD)
7.3.2.1 Company overview
7.3.2.2 Financial performance
7.3.2.3 Products benchmarking
7.3.2.4 Geographic footprint
7.3.2.5 Strategic initiatives
7.3.3 AstraZeneca
7.3.3.1 Company overview
7.3.3.2 Financial performance
7.3.3.3 Products benchmarking
7.3.3.4 Geographic footprint
7.3.3.5 Strategic initiatives
7.3.4 Novartis AG
7.3.4.1 Company overview
7.3.4.2 Financial performance
7.3.4.3 Products benchmarking
7.3.4.4 Geographic footprint
7.3.4.5 Strategic initiatives
7.3.5 Bristol-Myers Squibb Company
7.3.5.1 Company overview
7.3.5.2 Financial performance
7.3.5.3 Products benchmarking
7.3.5.4 Geographic footprint
7.3.5.5 Strategic initiatives
7.3.6 Allergan Plc
7.3.6.1 Company overview
7.3.6.2 Financial performance
7.3.6.3 Products benchmarking
7.3.6.4 Geographic footprint
7.3.6.5 Strategic initiatives
7.3.7 Novo Nordisk A/S
7.3.7.1 Company overview
7.3.7.2 Financial performance
7.3.7.3 Products benchmarking
7.3.7.4 Geographic footprint
7.3.7.5 Strategic initiatives
7.3.8 Boehringer Ingelheim
7.3.8.1 Company overview
7.3.8.2 Financial performance
7.3.8.3 Products benchmarking
7.3.8.4 Geographic footprint
7.3.8.5 Strategic initiatives
7.3.9 Pfizer Inc
7.3.9.1 Company overview
7.3.9.2 Financial performance
7.3.9.3 Products benchmarking
7.3.9.4 Geographic footprint
7.3.9.5 Strategic initiatives

List of Tables

Table 1 Factors used in segment share estimation
Table 2 North America NASH biomarkers market, by country, 2014 - 2025 (USD Million)
Table 3 North America NASH biomarkers market, by type, 2014 - 2025 (USD Million)
Table 4 North America NASH biomarkers market, by end-use, 2014 - 2025 (USD Million)
Table 5 U.S. NASH biomarkers market, by type, 2014 - 2025 (USD Million)
Table 6 U.S. NASH biomarkers market, by end-use, 2014 - 2025 (USD Million)
Table 7 Canada NASH biomarkers market, by type, 2014 - 2025 (USD Million)
Table 8 Canada NASH biomarkers market, by end-use, 2014 - 2025 (USD Million)
Table 9 Europe NASH biomarkers market, by country, 2014 - 2025 (USD Million)
Table 10 Europe NASH biomarkers market, by type, 2014 - 2025 (USD Million)
Table 11 Europe NASH biomarkers market, by end-use, 2014 - 2025 (USD Million)
Table 12 Germany NASH biomarkers market, by type, 2014 - 2025 (USD Million)
Table 13 Germany NASH biomarkers market, by end-use, 2014 - 2025 (USD Million)
Table 14 UK NASH biomarkers market, by type, 2014 - 2025 (USD Million)
Table 15 UK NASH biomarkers market, by end-use, 2014 - 2025 (USD Million)
Table 16 Asia Pacific NASH biomarkers market, by country, 2014 - 2025 (USD Million)
Table 17 Asia Pacific NASH biomarkers market, by type, 2014 - 2025 (USD Million)
Table 18 Asia Pacific NASH biomarkers market, by end-use, 2014 - 2025 (USD Million)
Table 19 JapanNASH biomarkers market, by type, 2014 - 2025 (USD Million)
Table 20 JapanNASH biomarkers market, by end-use, 2014 - 2025 (USD Million)
Table 21 China NASH biomarkers market, by type, 2014 - 2025 (USD Million)
Table 22 China NASH biomarkers market, by end-use, 2014 - 2025 (USD Million)
Table 23 India NASH biomarkers market, by Type, 2014 - 2025 (USD Million)
Table 24 India NASH biomarkers market, by End-use, 2014 - 2025 (USD Million)
Table 25 Latin America NASH biomarkersmarket, by country, 2014 - 2025 (USD Million)
Table 26 Latin AmericaNASH biomarkers market, by type, 2014 - 2025 (USD Million)
Table 27 Latin AmericaNASH biomarkers market, by end-use, 2014 - 2025 (USD Million)
Table 28 Brazil NASH biomarkers market, by type, 2014 - 2025 (USD Million)
Table 29 Brazil NASH biomarkers market, by end-use, 2014 - 2025 (USD Million)
Table 30 Mexico NASH biomarkers market, by type, 2014 - 2025 (USD Million)
Table 31 Mexico NASH biomarkers market, by end-use, 2014 - 2025 (USD Million)
Table 32 MEA NASH biomarkersmarket, by country, 2014 - 2025 (USD Million)
Table 33 MEA NASH biomarkers market, by type, 2014 - 2025 (USD Million)
Table 34 MEA NASH biomarkers market, by end-use, 2014 - 2025 (USD Million)
Table 35 South Africa NASH biomarkers market, by type, 2014 - 2025 (USD Million)
Table 36 South Africa NASH biomarkers market, by end-use, 2014 - 2025 (USD Million)

List of Figures

Figure 1 Market summary
Figure 2 Market trends & outlook
Figure 3 Market segmentation & scope
Figure 4 Market driver relevance analysis (Current & future impact)
Figure 5 Market restraint relevance analysis (Current & future impact)
Figure 6 Penetration & Growth Prospect Mapping
Figure 7 SWOT Analysis, By Factor (political & legal, economic and technological)
Figure 8 Porter’s Five Forces Analysis
Figure 9 NASH biomarkers market, Type outlook:Key takeaways
Figure 10 NASH biomarkers market: Type movement analysis
Figure 11 Serum biomarkers market, 2014 - 2025 (USD Million)
Figure 12 Hepatic fibrosis biomarkers market, 2014 - 2025 (USD Million)
Figure 13 Apoptosis biomarkers market, 2014 - 2025 (USD Million)
Figure 14 Oxidative stress biomarkers market, 2014 - 2025 (USD Million)
Figure 15 Others market, 2014 - 2025 (USD Million)
Figure 16 NASH biomarkers market, End-use outlook:Key takeaways
Figure 17 NASH biomarkers market: End-use movement analysis
Figure 18 Pharma & CRO industry market, 2014 - 2025 (USD Million)
Figure 19 Hospitals market, 2014 - 2025 (USD Million)
Figure 20 Diagnostic Labs market, 2014 - 2025 (USD Million)
Figure 21 Academic research institutes market, 2014 - 2025 (USD Million)
Figure 22 Regional market place: Key takeaways
Figure 23 Regional outlook, 2016& 2025
Figure 24 Strategy framework
Figure 25 Market participation and categorization

Companies Mentioned

  • GENFIT SA
  • Gilead Sciences, Inc. (GILD)
  • AstraZeneca
  • Novartis AG
  • Bristol-Myers Squibb Company
  • Allergan Plc
  • Novo Nordisk A/S
  • Boehringer Ingelheim
  • Pfizer Inc